Group 1 - The company did not distribute cash dividends or issue bonus shares during the reporting period [3] - The company’s controlling shareholder and actual controller did not change during the reporting period [5] - The company’s subsidiary, Beijing Liangyuan Biomedical Research Co., Ltd., received approval for clinical trials of a new drug for late-stage solid tumors [5][6] Group 2 - The company plans to distribute cash dividends of 2.493056 yuan per 10 shares, totaling approximately 121.18 million yuan, with the record date set for July 9, 2025 [5] - All directors attended the board meeting to review the report [2] - The company has ensured that the information disclosed is true, accurate, and complete [6]

证券代码：300109 证券简称：新开源 公告编号：2025-032 博爱新开源医疗科技集团股份有限公司 第五届董事会第十六次会议决议公告 经与会董事认真审议，会议形成了如下决议： （一）审议通过《关于 2025 年半年度报告及其摘要的议案》 董事会认为，公司 2025 年半年度报告全文及摘要的编制程序、内容和格式 符合法律、行政法规和中国证监会的有关规定，报告内容真实、准确、完整地反 映了公司 2025 年半年度的实际情况，不存在任何虚假记载、误导性陈述或者重 大遗漏。 公司董事会审计委员会已审议通过本议案。 公司监事会对本议案发表了审核意见。 本公司及其董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、董事会会议召开情况 博爱新开源医疗科技集团股份有限公司（以下简称"公司"或"新开源"） 第五届董事会第十六次会议于 2025 年 8 月 25 日上午在公司三楼会议室以现场加 通讯的表决方式召开，本次会议通知已于 2025 年 8 月 13 日以电子邮件形式发出。 本次会议由公司董事长张军政先生主持，应出席董事 9 名，实际出席董事 9 名，公司部分监事和高级管理人员列 ...

Group 1 - The meeting of the fifth supervisory board of Boai Xinkaiyuan Medical Technology Group Co., Ltd. was held on August 25, 2025, with all three supervisors present [1][2] - The supervisory board approved the procedures for the preparation and review of the 2025 semi-annual report and its summary, confirming compliance with relevant laws and regulations [1] - The report content was deemed to accurately and completely reflect the actual situation of the listed company, with no false records or misleading statements [1]

（文章来源：证券日报） 证券日报网讯 8月26日晚间，新开源发布公告称，公司第五届董事会第十六次会议审议通过了《关于 2025年半年度报告及其摘要的议案》。 ...

Core Insights - The company reported a revenue of 644,014,332.79 yuan for the first half of 2025, representing a year-on-year decline of 12.36% [1] - The net profit attributable to shareholders of the listed company was 138,956,706.00 yuan, which reflects a year-on-year decrease of 34.74% [1]

Group 1 - The company announced that its fifth supervisory board's twelfth meeting approved the proposal regarding the 2025 semi-annual report and its summary [2]

Financial Performance - The company's operating revenue for the current reporting period is approximately 644 million yuan, a decrease from 734 million yuan in the same period last year, representing a decline of about 12.3% [1] - The net profit attributable to shareholders is approximately 139 million yuan, down from 213 million yuan year-on-year, indicating a decrease of about 34.2% [1] - The net profit after deducting non-recurring gains and losses is approximately 129 million yuan, compared to 218 million yuan in the previous year, reflecting a decline of about 40.7% [1] - The net cash flow from operating activities is approximately 74 million yuan, down 52.97% from 158 million yuan in the same period last year [24] - Basic earnings per share are 0.29 yuan, down from 0.45 yuan year-on-year [1] Asset and Liability Changes - As of the end of the current reporting period, total assets amount to approximately 4.695 billion yuan, an increase from 4.372 billion yuan at the end of the previous year [1] - The net assets attributable to shareholders are approximately 3.779 billion yuan, up from 3.638 billion yuan at the end of the previous year [1] - Long-term borrowings have increased by 674.28%, contributing to a rise in total assets ratio by 2.93 percentage points [38] - The company's inventory value is 400 million yuan, accounting for 10.59% of net assets, with an increase of approximately 22.79 million yuan [41] Profitability Metrics - The weighted average return on equity for the first half of 2025 is 3.75%, a decrease of 2.16 percentage points compared to the previous year [23] - The company's gross profit margin has shown fluctuations, with the latest data indicating a decline compared to industry averages [19] Business Segments - The company operates in two main sectors: fine chemicals and precision medicine, with a focus on producing and selling PVP series products and developing a medical service platform [9] - The revenue composition for the first half of 2025 includes various product lines, with significant contributions from PVP products and precision medical services [15] Market Valuation - As of August 26, the company's price-to-earnings ratio (TTM) is approximately 33.37, the price-to-book ratio (LF) is about 2.44, and the price-to-sales ratio (TTM) is around 6.07 [1]

Group 1 - The core point of the article is that GLM-4.5, a competitor of OpenAI, is set to release a new open-source model tonight [1] Group 2 - Insiders have confirmed that the release will indeed take place tonight [1]

| 上市公司的子公司 | 长沙三济生物科技 | 子公司 | 其他应收款 | 17,260,608.58 | - | 187,289.35 | 4,400,000.00 | 13,047,897.93 | 资金往来 | 非经营性往来 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 及其附属企业 | 有限公司 | | | | | | | | | | | 上市公司的子公司 及其附属企业 | 苏州东胜兴业科学 仪器有限公司 | 子公司 | 其他应收款 | 10,299,856.16 | - | - | - | 10,299,856.16 | 资金往来 | 非经营性往来 | | 上市公司的子公司 及其附属企业 | 新开源（焦作）高 分子材料有限公司 | 子公司 | 其他应收款 | 50,000.00 | - | - | - | 50,000.00 | 资金往来 | 非经营性往来 | | 上市公司的子公司 及其附属企业 | 新开源（上海）医 疗科技有限公司 | 子公司 | 其他应收款 | - | 3,532,918.94 | ...

一、报告期内公司经营情况 博爱新开源医疗科技集团股份有限公司 2025年半年度财务报告 2025年上半年，公司在复杂多变的市场环境中围绕年度战略目标稳步推进各 项工作，既取得了阶段性成果，也面临一些挑战，具体情况如下： 报告期内，公司实现营业收入64,401.43万元，比上年同期下降12.36%；实现 营业利润16,797.29万元，比上年同期下降34.35%；实现归属于母公司的净利润 13,895.67万元，比上年同期下降34.74%；每股收益0.29元，比上年同期下降35.56%。 利润下降的主要原因是由于本期公司化工板块产品售价随市场情况调整所致。 报告期内，营业成本36,723.45万元，比上年同期增长11.41%，主要是因为产 品销量增加所致；销售费用2,742.95万元，比上年同期增长2.64%，与去年同期基 本持平；管理费用6,433.49万元，比上年同期下降10.34%，主要是因为本期股权 激励成本摊销金额下降所致；研发费用4,149.54万元，比去年同期增长15.43%， 主要是中站公司研发投入增加所致；财务费用-1,666.90万元，比上年同期下降 133.22%，主要原因为本期公司汇兑收 ...